Deficiency of the Interleukin-1 Receptor Antagonist (DIRA)
Deficiency of the interleukin-1 receptor antagonist (DIRA) is a rare and very serious inherited autoinflammatory disease that usually begins in the first weeks of life. It is caused by mutations in the IL1RN gene, which leave the body without the IL-1 receptor antagonist protein, so it cannot "switch off" inflammation driven by interleukin-1.
At Haute-Derma, we treat DIRA as both a dermatologic and a systemic emergency. Early diagnosis and targeted treatment not only calm severely damaged skin but are vital to preventing permanent bone and organ complications.
Our Approach to Treating DIRA
Our specialists at Haute-Derma manage DIRA through close multidisciplinary collaboration. Because DIRA can easily be mistaken for sepsis or neonatal pustular psoriasis, our process focuses on pinning down the genetic cause from the very start.
We are at the forefront of using replacement therapy for the missing IL-1 receptor antagonist, which brings children to a stable state quickly. Our care does not stop at the acute phase; it continues throughout the child's development to support the healthiest possible growth.
Our DIRA management pathway includes:
- Urgent genetic testing to identify the IL1RN mutation.
- Biologic replacement therapy for immediate control of inflammation.
- Ongoing monitoring of bone structure and growth to prevent long-term disability.
How DIRA Is Diagnosed at Haute-Derma
At Haute-Derma, we follow a rigorous process to distinguish DIRA from conditions with similar symptoms:
- Assessing the newborn's clinical picture: We look for the characteristic triad of a widespread pustular rash, painful swollen joints and diffuse periostitis.
- Acute inflammatory markers: We track very high neutrophil counts, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), even when there is no evidence of infection.
- Imaging (X-ray/MRI): Reveals periostitis, widening of the bone ends and the rib changes typical of DIRA.
- IL1RN gene sequencing: The gold standard for confirming IL-1 receptor antagonist deficiency.
- Differential diagnosis: We rule out neonatal sepsis, pustular psoriasis (DITRA) and CANDLE syndrome.
How Is DIRA Treated at Haute-Derma?
Because people with DIRA completely lack the body's natural IL-1 brake, we use direct replacement therapy:
- Anakinra (recombinant IL-1RA): This is a life-saving treatment. Anakinra takes the place of the missing antagonist and blocks IL-1 receptors. At Haute-Derma, most children with DIRA respond dramatically, with inflammation and skin lesions almost completely clearing after the first injections.
- Dose adjustment as the child grows: Children grow quickly, so our doctors closely monitor weight and laboratory markers to fine-tune the biologic dose.
- Managing bone damage: We work with pediatric orthopedic specialists to monitor and rehabilitate inflamed bones so the child can move normally.
- Preventing multi-organ failure: Continuous control of systemic inflammation prevents organ failure from a chronic cytokine storm.
